Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: PLAVIX

« Back to Dashboard
Plavix is a drug marketed by Sanofi Aventis Us and is included in one NDA. It is available from twelve suppliers. There are two patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in PLAVIX is clopidogrel bisulfate. There are fifty-one drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the clopidogrel bisulfate profile page.

Summary for Tradename: PLAVIX

Suppliers / Packagers: see list27

Pharmacology for Tradename: PLAVIX

Clinical Trials for: PLAVIX

Effect of Clopidogrel (Plavix) on Postoperative Bleeding in Patients Undergoing Coronary Artery Bypass Surgery.
Status: Completed Condition: Coronary Artery Disease

Clopidogrel Bioequivalence Study in Healthy Subjects
Status: Completed Condition: Bioequivalence, AUC, Cmax, Pharmacokinetics

Clopidogrel PGX Bench to Bedside
Status: Completed Condition: Metabolism of Clopidogrel

Aspirin and Plavix Following Coronary Artery Bypass Grafting
Status: Terminated Condition: Coronary Graft Patency

A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.
Status: Completed Condition: Healthy

Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy
Status: Recruiting Condition: Diabetes Type 2; Diabetic Nephropathy; Vascular Disease

Clopidogrel Pharmacogenomics Project
Status: Completed Condition: Disease Susceptibility

Genotyping Guided Individualized Treatment of Clopidogrel and Ticagrelor in ACS
Status: Not yet recruiting Condition: CLOPIDOGREL, POOR METABOLISM of (Disorder)

Comparative Pharmacodynamics and Pharmacokinetics Study of Generic and Reference Clopidogrel Products
Status: Completed Condition: Pharmacodynamics

Phase 1 Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion With Clopidogrel in Healthy Subjects
Status: Not yet recruiting Condition: Drug Interaction

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us
clopidogrel bisulfate
TABLET;ORAL020839-001Nov 17, 1997RXNo6,504,030*PED<disabled>Y<disabled>
Sanofi Aventis Us
clopidogrel bisulfate
TABLET;ORAL020839-002Sep 20, 2007RXYes6,504,030*PED<disabled>Y<disabled>
Sanofi Aventis Us
clopidogrel bisulfate
TABLET;ORAL020839-001Nov 17, 1997RXNo6,429,210*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: PLAVIX

Drugname Dosage Strength RLD Submissiondate
clopidogrel bisulfateTablets300 mgPlavix3/4/2009
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn